Novartis GRI Content Index
DISCLOSURE NUMBER |
DISCLOSURE TITLE |
UNGC PRINCIPLE |
UN SDG |
COMMENTS |
REFERENCE |
|---|---|---|---|---|---|
101 - FOUNDATION |
|||||
102 - GENERAL DISCLOSURES |
|||||
102-1 |
Name of the organization |
|
|
|
|
102-2 |
Activities, brands, products and services |
|
|
|
|
102-3 |
Location of headquarters |
|
|
|
|
102-4 |
Location of operations |
|
|
|
|
102-5 |
Ownership and legal form |
|
|
|
|
102-6 |
Markets served |
|
8, 10 |
|
|
102-7 |
Scale of the organization |
|
|
|
|
102-8 |
Information on employees and other workers |
6 |
8 |
|
|
102-9 |
Supply chain |
3, 4, 5, 6, 8, 10 |
|
|
|
102-10 |
Significant changes to the organization and its supply chain |
|
|
|
|
102-11 |
Precautionary principle or approach |
7 |
|
|
|
102-12 |
External initiatives |
|
|
|
Appendix: external initiatives and membership of associations |
102-13 |
Membership of associations |
1, 8 |
|
|
Appendix: external initiatives and membership of associations |
102-14 |
Statement from senior decision-maker |
|
|
|
|
102-16 |
Values, principles, standards, and norms of behavior |
1, 2, 3, 4, 5, 6, 8, 10 |
|
|
|
102-17 |
Mechanisms for advice and concerns about ethics |
10 |
|
|
|
102-18 |
Governance structure |
|
|
|
|
102-19 |
Delegating authority |
|
|
|
|
102-20 |
Executive-level responsibility for economic, environmental and social topics |
|
|
|
|
102-21 |
Consulting stakeholders on economic, environmental and social topics |
|
|
|
|
102-22 |
Composition of the highest governance body and its committees |
|
|
|
|
102-23 |
Chair of the highest governance body |
|
|
|
|
102-24 |
Nominating and selecting the highest governance body |
|
|
|
|
102-25 |
Conflicts of interest |
|
|
|
|
102-26 |
Role of highest governance body in setting purpose, values and strategy |
|
|
|
|
102-27 |
Collective knowledge of highest governance body |
|
|
|
|
102-28 |
Evaluating the highest governance body’s performance |
|
|
|
|
102-29 |
Identifying and managing economic, environmental and social impacts |
|
|
|
|
102-30 |
Effectiveness of risk management processes |
|
|
|
|
102-31 |
Review of economic, environmental and social topics |
|
|
|
|
102-32 |
Highest governance body’s role in sustainability reporting |
|
|
|
|
102-33 |
Communicating critical concerns |
|
|
|
|
102-34 |
Nature and total number of critical concerns |
|
|
Number and nature of concerns are not disclosed |
|
102-35 |
Remuneration policies |
|
|
|
|
102-36 |
Process for determining remuneration |
|
|
|
|
102-37 |
Stakeholders’ involvement in remuneration |
|
|
|
|
102-38 |
Annual total compensation ratio |
|
|
Information is confidential and not disclosed |
|
102-39 |
Percentage increase in annual total compensation ratio |
|
|
Information is confidential and not disclosed |
|
102-40 |
List of stakeholder groups |
|
|
|
|
102-41 |
Collective bargaining agreements |
3 |
8 |
|
|
102-42 |
Identifying and selecting stakeholders |
|
|
|
|
102-43 |
Approach to stakeholder engagement |
|
|
|
|
102-44 |
Key topics and concerns raised |
|
|
|
|
102-45 |
Entities included in the consolidated financial statements |
|
|
|
|
102-46 |
Defining report content and topic boundaries |
|
|
|
|
102-47 |
List of material topics |
|
3, 8, 9, 10, 13 |
|
|
102-48 |
Restatements of information |
|
|
|
|
102-49 |
Changes in reporting |
|
|
|
|
102-50 |
Reporting period |
|
|
|
January-December, 2021 |
102-51 |
Date of most recent report |
|
|
|
02.02.21 |
102-52 |
Reporting cycle |
|
|
|
|
102-53 |
Contact point for questions regarding the report |
mailto: james.wallace@novartis.com |
|
||
102-54 |
Claims of reporting in accordance with the GRI Standards |
|
|
|
|
102-55 |
GRI Content Index |
|
|
|
|
102-56 |
External assurance |
|
|
|
Independent Assurance Report on the 2021 Novartis in Society Integrated Report |
DISCLOSURE NUMBER |
DISCLOSURE TITLE |
UNGC PRINCIPLE |
UN SDG |
COMMENTS |
REFERENCE |
|---|---|---|---|---|---|
103 - MANAGEMENT APPROACH |
|||||
103-1 |
Explanation of the material topic and its boundary |
|
3, 8, 9, 10, 13 |
|
Our 2021 materiality assessment |
103-2 |
The management approach and its components |
|
3, 8, 9, 10, 13 |
|
Novartis in Society Integrated Report 2021 |
103-3 |
Evaluation of the management approach |
|
3, 8, 9, 10, 13 |
|
|
DISCLOSURE NUMBER |
DISCLOSURE TITLE |
UNGC PRINCIPLE |
UN SDG |
COMMENTS |
REFERENCE |
|---|---|---|---|---|---|
200 - ECONOMIC |
|||||
201-1 |
Direct economic value generated and distributed |
|
8 |
|
|
201-2 |
Financial implications and other risks and opportunities due to climate change |
7, 8, 9 |
13 |
|
|
203-2 |
Significant indirect economic impacts |
|
8, 9, 10, 13 |
|
|
204-1 |
Proportion of spending on local suppliers |
|
|
|
|
205-1 |
Operations assessed for risks related to corruption |
10 |
|
|
|
206-1 |
Legal actions for anti-competitive behavior, anti-trust and monopoly practices |
|
|
|
|
207-1 |
Approach to tax |
|
|
|
|
207-2 |
Tax governance, control, and risk management |
|
|
|
|
DISCLOSURE NUMBER |
DISCLOSURE TITLE |
UNGC PRINCIPLE |
UN SDG |
COMMENTS |
REFERENCE |
||
|---|---|---|---|---|---|---|---|
300 - ENVIRONMENT |
|||||||
301-2 |
Recycled input materials used |
8 |
8 |
|
Enhancing environmental sustainability |
||
301-3 |
Reclaimed products and their packaging materials |
8 |
8 |
|
|||
302-1 |
Energy consumption within the organization |
7, 8, 9 |
7, 8, 13 |
|
Enhancing environmental sustainability |
||
302-2 |
Energy consumption outside of the organization |
8 |
7, 8, 13 |
|
Enhancing environmental sustainability |
||
302-3 |
Energy intensity |
8 |
7, 8, 13 |
|
Enhancing environmental sustainability |
||
302-4 |
Reduction of energy consumption |
7, 8, 9 |
7, 8, 13 |
|
Enhancing environmental sustainability |
||
302-5 |
Reductions in energy requirements of products and services |
8, 9 |
7, 8, 13 |
|
Enhancing environmental sustainability |
||
303-1 |
Interactions with water as a shared resource |
7, 8 |
6, 8 |
We recognize the gap on the revised GRI 303 standards for Water and Effluents 2018, and are developing a plan to align with the GRI in the future. |
Enhancing environmental sustainability |
||
303-2 |
Management of water discharge-related impacts |
7, 8, 9 |
6, 8 |
|
Enhancing environmental sustainability |
||
303-3 |
Water withdrawal |
7, 8, 19 |
6, 8 |
|
Enhancing environmental sustainability |
||
305-1 |
Direct (Scope 1) GHG emissions |
7, 8 |
3, 13 |
|
Enhancing environmental sustainability |
||
305-2 |
Energy indirect (Scope 2) GHG emissions |
7, 8 |
3, 13 |
|
Enhancing environmental sustainability |
||
305-3 |
Other indirect (Scope 3) GHG emissions |
7, 8 |
3, 13 |
|
Enhancing environmental sustainability |
||
305-4 |
GHG emissions intensity |
8 |
13 |
|
Enhancing environmental sustainability |
||
305-5 |
Reduction of GHG emissions |
7, 8, 9 |
3, 13 |
|
Enhancing environmental sustainability |
||
305-6 |
Emissions of ozone-depleting substances (ODS) |
7, 8, 9 |
3, 13 |
|
Enhancing environmental sustainability |
||
305-7 |
Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions |
7, 8, 9 |
3, 13 |
|
Enhancing environmental sustainability |
||
306-1 |
Waste generation and significant waste-related impacts |
7, 8, 9 |
3, 6 |
|
Enhancing environmental sustainability |
||
306-2 |
Management of significant waste-related impacts |
7, 8 |
3, 6 |
|
Enhancing environmental sustainability |
||
308-1 |
New suppliers that were screened using environmental criteria |
8 |
|
|
|||
308-2 |
Negative environmental impacts in the supply chain and actions taken |
|
|
|
|||
|
|||||||
DISCLOSURE NUMBER |
DISCLOSURE TITLE |
UNGC PRINCIPLE |
UN SDG |
COMMENTS |
REFERENCE |
||
|---|---|---|---|---|---|---|---|
400 - SOCIAL |
|||||||
401-1 |
New employee hires and employee turnover |
6 |
8 |
|
|||
403-1 |
Occupational health and safety management system |
|
3 8 |
We recognize the gap on the revised GRI 403 standards for Occupational Helath and Safety 2018, and are developing a plan to align with the GRI in the future. |
|||
403-2 |
Hazard identification, risk assessment, and incident investigation |
|
3 8 |
|
|||
403-3 |
Occupational health services |
|
3 8 |
|
Supporting and protecting our employees |
||
403-5 |
Worker training on occupational health and safety |
|
3 8 |
|
Ensuring patient health and safety |
||
403-6 |
Promotion of worker health |
|
3 8 |
|
Supporting and protecting our employees |
||
403-9 |
Work-related injuries |
|
3 8 |
|
Unleash the power of our people |
||
404-1 |
Average hours of training per year, per employee |
6 |
8 |
|
|||
404-2 |
Programs for upgrading employee skills and transition assistance programs |
|
|
|
|||
405-1 |
Diversity of governance bodies and employees |
6 |
8 10 |
|
|||
409-1 |
Operations and suppliers at significant risk for incidents of forced or compulsory labor |
4 |
8 |
|
|||
412-1 |
Operations that have been subject to human rights reviews or impact assessments |
1 |
|
|
|||
414-1 |
New suppliers that were screened using social criteria |
|
|
|
|||
414-2 |
Negative social impacts in the supply chain and actions taken |
|
|
|
|||
415-1 |
Political contributions |
|
|
|
Novartis Responsible Lobbying Disclosures |
||
416-2 |
Incidents of noncompliance concerning the health and safety indicators impacts of products and services |
|
|
|
|||
417-1 |
Requirements for product and service information and labeling |
|
|
We operate in a strictly regulated industry; this information is obligatory for us to have a license to operate |
|||
418-1 |
Substantiated complaints concerning breaches of customer privacy and losses of customer data |
|
|
|
|||
419-1 |
Noncompliance with laws and regulations in the social and economic area |
|
|
|
|||
|
|||||||